Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Korro Bio, Inc. (KRRO)

Healthcare Biotechnology
10.40 $
-0.8% vs. previous close
Closing price · As of: 31. Jul 2026

Who owns Korro Bio, Inc. (KRRO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 65.0% of the shares are freely tradable; institutional investors hold 96.9%.

Ownership Structure

Institutional ownership
96.9%
Insiders
0.9%
Float
65.0%
Short % of float
10.3%
Shares Outstanding
14Mio.

Largest Shareholders

Institutions

Institutions KRRO
Name Stake (%) Shares Change (%) Date
Lynx1 Capital Management, LP 10.67 1,538,296 +126.9 03/31/2026
NEA Management Company, LLC 9.00 1,297,893 +19.0 03/31/2026
Atlas Venture Life Science Advisors, LLC 7.88 1,137,149 +0.0 03/31/2026
Balyasny Asset Management LLC 7.21 1,040,054 +0.0 03/31/2026
VR Adviser, LLC 7.00 1,009,500 +0.0 03/31/2026
Affinity Asset Advisors, LLC 4.90 706,904 +0.0 03/31/2026
Nantahala Capital Management, LLC 4.58 660,036 +10.0 03/31/2026
ADAR1 Capital Management LLC 3.74 540,054 +0.0 03/31/2026
Vanguard Group Inc 3.39 489,639 +23.8 12/31/2025
BlackRock Inc 3.19 460,006 +0.6 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
15. Jul 2026 Vincent Loic A Chief Scientific Officer Other 7,500 0.00
15. Jul 2026 Dolan Oliver Senior Vice President, Finance Other 5,500 0.00
15. Jul 2026 Cerio Jeffrey General Counsel Other 6,500 0.00
15. Jul 2026 Chappell Todd Chief Operating Officer Other 7,500 0.00

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?